LEO Pharma Secures FDA Approval for ANZUPGO® (Delgocitinib) Cream in the U.S.
LEO Pharma Achieves Landmark FDA Approval for ANZUPGO® (Delgocitinib) Cream to Treat Chronic Hand Eczema in U.S. Adults LEO Pharma, a global leader in medical dermatology with a deep-rooted focus…
Flatiron Health Triples Global Oncology Network to Boost Multinational Research
Flatiron Health Triples Global Oncology Research Network to Power Multinational Real-World Evidence Generation Flatiron Health, a healthtech company pioneering the use of real-world data (RWD) to transform cancer care and…
Huonslab Earns Formulation Patent for HYDIZYME™, Its Recombinant Human Hyaluronidase Product
Huonslab Strengthens HYDIZYME™ Pipeline with Formulation Patent, Targeting 2026 Market Launch Huonslab Co., Ltd., a subsidiary of Huons Global (KOSDAQ:084110), has taken a major step forward in its mission to…
Crossbow Therapeutics Nominates Second Cancer Drug Candidate, CBX-663
Crossbow Therapeutics Advances Second TCR-Mimetic Cancer Therapy Candidate, CBX-663, Targeting TERT Across Broad Range of Tumors Crossbow Therapeutics, Inc., a biotechnology company pioneering a new class of T-cell receptor (TCR)-mimetic…
Study Validates Aptar’s Nasal Spray for Direct Brain Delivery of Alzheimer’s Drug
Aptar’s Nasal Delivery System Helps Validate Breakthrough Alzheimer’s Treatment in Wake Forest Study In a major advancement for Alzheimer’s research and the evolving field of drug delivery science, AptarGroup, Inc.…
CVS Health Launches State-of-the-Art Workforce Innovation and Talent Center in Columbus
CVS Health Unveils New Workforce Innovation and Talent Center in Columbus to Empower Local Communities Through Job Training and Health Services In a powerful step toward strengthening community health and…
Lantern Pharma Achieves Complete Response with LP-284 in Tough Lymphoma Case
Lantern Pharma Achieves Landmark Complete Response in Heavily Pretreated Lymphoma Patient, Validating AI-Driven Precision Oncology Strategy Lantern Pharma’s LP-284 demonstrates transformative clinical potential in one of the most difficult-to-treat blood…
ReAlta Reports RLS-0071 Cuts Brain Inflammation in Preclinical HIE Model
ReAlta Life Sciences Publishes Preclinical Data Showing RLS-0071 Reduces Brain Inflammation in Neonatal Hypoxic-Ischemic Encephalopathy Model ReAlta Life Sciences, Inc., a clinical-stage biopharmaceutical company advancing therapies that rebalance the body’s…
YourChoice Therapeutics Celebrates Second Publication in Nature
YourChoice Therapeutics Advances Male Contraception with Second Nature Portfolio Publication Showcasing Human Trial Data for YCT-529 YourChoice Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of hormone-free contraceptive solutions,…
Charles River Collaborates with Elly to Advance Gene Therapies for Rare Diseases
Charles River Teams Up with Elly’s Team to Accelerate Gene Therapy for Ultra-Rare NEDAMSS Disorder Charles River Laboratories International, Inc. (NYSE: CRL), a global leader in early-stage drug development and…
Alloy Therapeutics and KSAC Partner to Boost Global Growth of Japanese Biotech Startups
Alloy Therapeutics and KSAC Forge Strategic Alliance to Propel Global Growth of Japanese Life Science Startups Alloy Therapeutics Co. Ltd. (“Alloy Japan”) has entered into a strategic Memorandum of Understanding…
Takeda Secures FDA 510(k) Clearance for HyHub™ and HyHub™ Duo to Streamline HYQVIA® Delivery
Takeda Gains FDA 510(k) Clearance for HyHub™ and HyHub™ Duo to Enhance HYQVIA® Administration Experience for Patients with Primary Immunodeficiency and CIDP Takeda (TSE:4502/NYSE:TAK), a global biopharmaceutical leader, announced that…